Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Roche has signed a voluntary license agreement providing its popular influenza antiviral drug Xofluza (baloxavir marboxil) for generic drugmakers to copy in 129 developing countries. | Roche has signed a voluntary license agreement providing its popular influenza antiviral drug Xofluza for generic drugmakers to copy in 129 developing countries.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise

Studies have shown baloxavir to be a standout among antivirals commonly used for influenza

The program will sell Xofluza through three pharmacies with a $50 cash pay option, which is 70% lower than the pill's current…

On the heels of a European Commission probe into whether Sanofi “disparaged” one of its flu vaccine rivals in the marketing of…

After a prior misfire in demonstrating its protease inhibitor ensitrelvir’s potential as a COVID-19 treatment for U.S. | After a…

Eli Lilly plans to launch its oral obesity treatment Foundayo in Europe by the end of this year or early 2027, focusing on the…

Reporting a new miss in one indication, Karyopharm Therapeutics is plowing ahead with plans to advance its XPO1 inhibitor Xpovio…